Human IL-2 R gamma / CD132 Protein, His Tag (MALS verified)
分子別名(Synonym)
IL2RG,CD132,CIDX,IMD4,P64,SCIDX,SCIDX1,gammaC
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-2 R gamma, His Tag (ILA-H52H5) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Asn 254 (Accession # P31785-1).
Predicted N-terminus: Leu 23
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 29.3 kDa. The protein migrates as 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景(Background)
IL-2R是一種異三聚體蛋白,與細(xì)胞因子IL-2結(jié)合并產(chǎn)生反應(yīng)。鑒定出三條不同的IL-2R鏈,稱為α、β和γ,它們是非共價結(jié)合的。α鏈和β鏈參與結(jié)合IL-2,而細(xì)胞因子相互作用后的信號轉(zhuǎn)導(dǎo)由γ鏈和β亞基進行。IL-2R的α鏈可以在受體與IL-2相互作用之前與β鏈結(jié)合。單獨的γ鏈對IL-2的親和力非常弱,但在配體與α/β異二聚體結(jié)合后,γ鏈被招募到復(fù)合物中,形成非常穩(wěn)定的大分子四元配體/受體復(fù)合物。
白細(xì)胞介素-2受體亞基γ(IL2RG),也稱為細(xì)胞因子受體共同亞基γ,CD抗原CD132,gammaC,p64,屬于I型細(xì)胞因子受體家族或5型亞家族。IL2RG位于骨髓中未成熟造血細(xì)胞的表面。IL2RG缺陷是嚴(yán)重聯(lián)合免疫缺陷X連鎖T細(xì)胞陰性/B細(xì)胞陽性/NK細(xì)胞陰性(XSCID)的原因。
關(guān)鍵字: IL-2 R gamma;IL2RG蛋白;IL2RG重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。